Patents by Inventor Shin-ichiro Imai
Shin-ichiro Imai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12150950Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: GrantFiled: September 21, 2023Date of Patent: November 26, 2024Assignee: Washington UniversityInventors: Shin-Ichiro Imai, Rajendra Apte
-
Publication number: 20240009222Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: ApplicationFiled: September 21, 2023Publication date: January 11, 2024Applicant: Washington UniversityInventors: Shin-ichiro Imai, Rajendra Apte
-
Publication number: 20230338407Abstract: Various methods and compositions for treating age-associated conditions and other medical conditions, such as muscle diseases, type 2 diabetes, and/or obesity are described. Methods of enhancing cellular uptake of NMN and stimulating NAD+ production are further described. Various mammalian cells and mammalian cell lines are described including those comprising a cDNA encoding a Slc12a8 protein. Gene therapy vectors comprising a nucleic acid encoding Slc12a8 and non-human animals comprising an inactivating mutation in a Slc12a8 gene are also disclosed. Also described are methods for screening a candidate compound to identify compounds that promote NMN transport.Type: ApplicationFiled: January 30, 2023Publication date: October 26, 2023Applicant: Washington UniversityInventors: Shin-ichiro Imai, Alessia Grozio
-
Patent number: 11793824Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: GrantFiled: January 15, 2021Date of Patent: October 24, 2023Assignee: Washington UniversityInventors: Shin-ichiro Imai, Rajendra Apte
-
Patent number: 11564936Abstract: Various methods and compositions for treating age-associated conditions and other medical conditions, such as muscle diseases, type 2 diabetes, and/or obesity are described. Methods of enhancing cellular uptake of NMN and stimulating NAD+ production are further described. Various mammalian cells and mammalian cell lines are described including those comprising a cDNA encoding a Slc12a8 protein. Gene therapy vectors comprising a nucleic acid encoding Slc12a8 and non-human animals comprising an inactivating mutation in a Slc12a8 gene are also disclosed. Also described are methods for screening a candidate compound to identify compounds that promote NMN transport.Type: GrantFiled: August 10, 2018Date of Patent: January 31, 2023Assignee: Washington UniversityInventors: Shin-ichiro Imai, Alessia Grozio
-
Publication number: 20220233443Abstract: The present invention relates to various compositions comprising NAMPT and/or mutant thereof, processes for preparing these compositions, and various methods of using these compositions to prevent or treat an age-associated condition in a subject. The present invention also relates to methods of increasing NMN and/or NAD+ biosynthesis in a cell.Type: ApplicationFiled: June 8, 2020Publication date: July 28, 2022Applicant: Washington UniversityInventors: Shin-Ichiro Imai, Mitsukuni Yoshida
-
Publication number: 20210346413Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: ApplicationFiled: January 15, 2021Publication date: November 11, 2021Applicant: Washington UniversityInventors: Shin-ichiro Imai, Rajendra Apte
-
Patent number: 10925888Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: GrantFiled: March 1, 2019Date of Patent: February 23, 2021Assignee: Washington UniversityInventors: Shin-ichiro Imai, Rajendra Apte
-
Publication number: 20200215087Abstract: Various methods and compositions for treating age-associated conditions and other medical conditions, such as muscle diseases, type 2 diabetes, and/or obesity are described. Methods of enhancing cellular uptake of NMN and stimulating NAD+ production are further described. Various mammalian cells and mammalian cell lines are described including those comprising a cDNA encoding a Slc12a8 protein. Gene therapy vectors comprising a nucleic acid encoding Slc12a8 and non-human animals comprising an inactivating mutation in a Slc12a8 gene are also disclosed. Also described are methods for screening a candidate compound to identify compounds that promote NMN transport.Type: ApplicationFiled: August 10, 2018Publication date: July 9, 2020Applicant: Washington UniversityInventors: Shin-ichiro Imai, Alessia Grozio
-
Publication number: 20190224223Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: ApplicationFiled: March 1, 2019Publication date: July 25, 2019Inventors: Shin-ichiro IMAI, Rajendra APTE
-
Patent number: 10258638Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: GrantFiled: October 13, 2017Date of Patent: April 16, 2019Assignee: Washington UniversityInventor: Shin-ichiro Imai
-
Publication number: 20180050054Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: ApplicationFiled: October 13, 2017Publication date: February 22, 2018Inventor: Shin-ichiro IMAI
-
Patent number: 9844561Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: GrantFiled: September 15, 2015Date of Patent: December 19, 2017Assignee: Washington UniversityInventors: Shin-ichiro Imai, Rajendra Apte
-
Publication number: 20160022712Abstract: Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.Type: ApplicationFiled: September 15, 2015Publication date: January 28, 2016Inventors: Shin-ichiro IMAI, Rajendra APTE
-
Patent number: 8652797Abstract: Methods of NAD-dependent of at least one lysine residue in an acetylated protein are disclosed. The methods include combining the acetylated protein with an isolated Sir2 protein or fragment that includes a core domain of the Sir2 protein. The Sir2 protein or fragment of the Sir2 protein can include a human Sir2 protein or a fragment of a human Sir2 protein.Type: GrantFiled: September 12, 2008Date of Patent: February 18, 2014Assignee: Massachusetts Institute of TechnologyInventors: Leonard Guarente, Shin-ichiro Imai, Christopher Armstrong
-
Patent number: 8642284Abstract: Methods of identifying agents which alter the NAD-dependent deacetylation activity of a Sir2 protein or a fragment of a Sir2 protein are disclosed. The acetylated protein can be a nuclear protein, such as a histone protein, or a cytoplasmic protein. The Sir2 protein employed in the methods can include at least a core domain of a Sir2 protein, such as a human Sir2 protein.Type: GrantFiled: December 13, 2000Date of Patent: February 4, 2014Assignee: Massachusetts Institute of TechnologyInventors: Leonard Guarente, Shin-Ichiro Imai, Christopher Armstrong
-
Patent number: 8546074Abstract: Methods for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound are described.Type: GrantFiled: June 14, 2012Date of Patent: October 1, 2013Assignees: Massachusetts Institute of Technology, Whitehead Institute for Biomedical ResearchInventors: Leonard P. Guarente, Homayoun Vaziri, Shin-Ichiro Imai
-
Publication number: 20130071378Abstract: Methods for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound are described.Type: ApplicationFiled: June 14, 2012Publication date: March 21, 2013Inventors: Leonard Guarente, Homayoun Vaziri, Shin-Ichiro Imai
-
Patent number: 8268575Abstract: The present invention generally relates to a nicotinamide adenine dinucleotide (NAD) biosynthesis system and methods of screening for NAD biosynthesis effectors. Among the various aspects of the present invention is the provision of an in vitro-reconstituted mammalian NAD biosynthesis system that can be used for the high-throughput screening of chemical activators and inhibitors for mammalian NAD biosynthesis. Another aspect of the invention provides a method of identifying a compound that effects in vivo activity of NAD metabolic enzymes. Further aspects of the invention include nucleic acid sequences, vectors, and transformed cells that can be used in the methods described herein.Type: GrantFiled: September 20, 2005Date of Patent: September 18, 2012Assignee: Washington UniversityInventors: Shin-Ichiro Imai, Javier R. Revollo, Andrew A. Grimm
-
Publication number: 20110123510Abstract: The present invention relates to methods of regulating biological functions in a mammal that are mediated, at least in part, by the circadian clock.Type: ApplicationFiled: September 24, 2010Publication date: May 26, 2011Applicant: WASHINGTON UNIVERSITYInventors: Shin-ichiro Imai, Joseph Bass